Many of us have shares in another Australian biotech (let call...

Many of us have shares in another Australian biotech (let call it biotech A)which has developed a generic pharmaceutical. Biotech A has licensed a large generic manufacturer to make, distribute and market the drug. As a result Biotech A will get 50% of the profits.

In the case of TIS we seem to be looking for a large commercial company to simply market and distribute Vitrogro. As I understand it TIS will still manufacture the product. If this is the case then the large company needs to do far less work and invest a far smaller amount of capital.

Therefore I pose the question, what will TIS's deal with the large commercial company be? Surely we should get well over 50% of the profits? I would be thinking 70 to 80% would be appropriate but then I have little experience in this area.

Any guidance from anyone?

Rev